# ARCKENS AstroShank (ERANET DMP)

## DMP TITLE

### ADMIN DETAILS

**Project Name:** Arckens-Holt AstroShank (ERANET DMP)

**Grant Title:** Astrocytes dysfunctions in Phelan-McDermid syndrome: from mechanisms towards new therapeutic strategies

**Principal Investigator / Researcher:** Lutgarde Arckens

**Project Data Contact:** Postdoc to be hired on the project

**Institution:** KU Leuven

### 1. GENERAL INFORMATION

**Name applicant**

Prof. Dr. Lutgarde Arckens

**FWO Project Number & Title**

Title: Astrocytes dysfunctions in Phelan-McDermid syndrome: from mechanisms towards new therapeutic strategies

Number: G0G4521N

**Abstract**

The lack of one copy of the SHANK3 gene is the main cause of the neuropsychiatric symptoms of Phelan- McDermid syndrome (PMS), a neurodevelopmental disorder characterized by intellectual disability and autistic-like deficits. To date, SHANK3-related syndromes have only been investigated from a neuronal perspective, but recent data have highlighted a possible involvement of astrocytic SHANK3 in the pathophysiology of PMS. Astrocyte-specific deletion of SHANK3 early in postnatal development is associated with impaired astrocyte maturation and recapitulates many of the main phenotypes of PMS mouse models, such as impaired synaptogenesis, repetitive behaviors and cognitive dysfunction. These findings suggest that defects in the postnatal maturation of SHANK3 deficient astrocytes may (at least partially) account for the neuronal dysmorphogenesis, synaptopathies, and behavioral impairments associated with SHANK3-related syndromes. By deleting and re-expressing astrocyte-specific SHANK3 in systems ranging from *in vitro* cultures to state-of-the-art animal models and next-generation brain organoids, we will be able to provide important new insights into the pathological mechanisms of neurodevelopment in PMS. These could guide development of therapies for PMS, and possibly other autism-spectrum disorders characterized by mGluR5 signaling dysfunction.

**Affiliation**

* KU Leuven

### 2. DATA DESCRIPTION

**Will you generate/collect new data and/or make use of existing data?**

* Generate new data

**Describe in detail the origin, type and format of the data (per dataset) and its (estimated) volume. This may be easiest in a table (see example) or as a data flow and per WP or objective of the project. If you reuse existing data, specify the source of these data. Distinguish data types (the kind of content) from data formats (the technical format).**

|  |  |  |  |
| --- | --- | --- | --- |
| Type of data | Format | Volume | How created |
|  | | | |
| Stocksheet plasmids for TRAP experiments | xlsx file | 450 KB | Repository of plasmids |
| Transcriptome/Translatome data from mice expressing TRAP constructs (lentiviral vector delivery) | BCL/FASTQ file | 3 TB | Ribosome pull-down followed by Illumina sequencing |
| Transcriptome/Translatome data from organoids expressing TRAP constructs (electroporation-based delivery) | BCL/FASTQ file | 3 TB | Ribosome pull-down followed by Illumina sequencing |

### 3. LEGAL AND ETHICAL ISSUES

**Will you use personal data? If so, shortly describe the kind of personal data you will use. Add the reference to your file in KU Leuven's Register of Data Processing for Research and Public Service Purposes (PRET application). Be aware that registering the fact that you process personal data is a legal obligation.**

* No

Privacy Registry Reference:

Short description of the kind of personal data that will be used:

**Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, add the reference to the formal approval by the relevant ethical review committee(s)**

* No (No animal experimentation at KU Leuven planned)

**Does your work possibly result in research data with potential for tech transfer and valorisation? Will IP restrictions be claimed for the data you created? If so, for what data and which restrictions will be asserted?**

* Yes

The project largely contains fundamental research that will generate insights for possible future valorisation. It holds a potential to medical translation or application in the clinic but only on the long run. There might be IP depending on the obtained results. This may involve the identification of molecules implemented in neurodevelopmental disorders (autism and others). If mechanisms or molecules being identified in the project are novel and promising for clinical application, possible IP protection will be considered, which will then be performed in consultation with LRD and VIB.

**Do existing 3rd party agreements restrict dissemination or exploitation of the data you (re)use? If so, to what data do they relate and what restrictions are in place?**

* No

### 4. DOCUMENTATION AND METADATA

**What documentation will be provided to enable reuse of the data collected/generated in this project?**

**Digital** **data:**

We will maintain a record of the following for the project (where applicable):

-Experimental design and protocol (.docx file)

-Abbreviations used (.docx file)

-Structure of the data (.docx file)

-Steps involved in data analysis and relevant analysis scripts

-Raw data (specific file format according to data type)

-Analyzed data (specific file format according to data type)

-Index file/read me file (.txt file) for every WP, linking the name, location (folder and subfolder on /server) and description of above-mentioned files.

**Physical** **data:**

Samples taken from experiments (in labs of the other partners) will be documented and stored upon arrival for up to three years after the end of the project. Storage will be in freezers.

**Will a metadata standard be used? If so, describe in detail which standard will be used. If no, state in detail which metadata will be created to make the data easy/easier to find and reuse.**

* Yes

The experiments are unique, but the data will be standardized according to data-type across experiments to make it easier to interpret the structure. Below, we list the metadata standards applicable to this project:

Metadata standards will be used for the genomics data ( <http://www.dcc.ac.uk/resources/metadata-standards/genome-metadata>). For all other data, metadata will be created using the Dublin core (http://www.dcc.ac.uk/resources/metadata-standards/dublin-core).

### 5. DATA STORAGE AND BACKUP DURING THE ERANET PROJECT

**Where will the data be stored?**

All digital data will be stored on servers centrally managed by ICTS KU Leuven and with back-up capacities (KU Leuven OneDrive, LargeVolume-storage).

We expect about 6 Tb of data to be stored.

The physical samples will be stored in freezers/fridges.

**How is backup of the data provided?**

We will use the back-up facilities of the KU Leuven ICTS.

**Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available then explain how this will be taken care of.**

* Yes

There is currently sufficient storage at KU Leuven ICTS.

**What are the expected costs for data storage and back up during the project? How will these costs be covered?**

Back-up cost per Tb (KU Leuven ICTS): 295€/year

Expected amount of data (6 Tb). Digital vault for private data: windows server (KU Leuven ICTS): 1770 €/year.

The costs will be covered by the running costs on the grant.

**Data security: how will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?**

All network storage is hosted in the KU Leuven ICTS data center, with a mirror in the second ICTS center, to provide disaster recovery and additional back-up capacity, thus guaranteeing long-term data availability. Access to data is conditioned by KU Leuven security groups. All data will be password protected.

### 6. DATA PRESERVATION AFTER THE ERANET PROJECT

**Which data will be retained for the expected 5 year period after the end of the project? In case only a selection of the data can/will be preserved, clearly state the reasons for this (legal or contractual restrictions, physical preservation issues, ...).**

**Digital** **data:** We will retain all data for the expected 5-year period. For most publications we expect that we will make the data publicly available on data repositories. Sequencing data will be submitted to public databases (EBI-ENA/NCBI- SRA), where they will be permanently archived to preserve access to the public.

**Physical** **data:** Fridge stocks of the plasmids will be available upon request. After the conclusion of the project, samples will be stored for up to three years after the end of the project. Storage will be in freezers.

**Where will the data be archived (= stored for the longer term)?**

We will use the back-up possibilities as proposed by KU Leuven ICTS, with servers centrally managed by the ICTS to store all digital data. Notebooks will be kept in the lab for at least 5 years, conform the KU Leuven RDM policy.

**What are the expected costs for data preservation during the retention period of 5 years? How will the costs be covered?**

We expect about 1770 EUR/year. These costs will be budgeted into the project.

### 7. DATA SHARING AND REUSE

**Are there any factors restricting or preventing the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)?**

* No

**Which data will be made available after the end of the project?**

Relevant neurobiological findings will be disseminated through publication in high profile, peer-reviewed international journals within the life science field. The data will be presented on (inter)national scientific field- specific meetings, e.g. EuroGlia, SfN and FENS etc.

Published data will be available to all. For most publications, we expect that we will make the data publicly available on data repositories.

**Where/how will the data be made available for reuse?**

* In an Open Access repository

Published experimental data will be made available through a data repository such as Genebank, FigShare (https://figshare.com/), Dryad (https://datadryad.org/) or https://zenodo.org/ depending on the type of data. We will explore the possibilities via online repositories and will use the website www.re3data.org.

**When will the data be made available?**

* Upon publication of the research results

**Who will be able to access the data and under what conditions?**

All team members have access as long as they are affiliated to KU Leuven. Once all files are released, anyone can use these data to generate new results, referring to the original publication and not for commercial use. Data will be released under a CC-BY-NC reuse license.

**What are the expected costs for data sharing? How will the costs be covered?**

The transfer costs depend on the data repository selected. Costs will be covered by project fund.

### 8. RESPONSIBILITIES

**Who will be responsible for data documentation & metadata?**

The PI (Lutgarde Arckens), and the day-to-day manager of the Eranet project (Postdoc to be hired).

**Who will be responsible for data storage & back up during the project?**

The PI (Lutgarde Arckens), and the day-to-day manager of the Eranet project (postdoc to be hired).

**Who will be responsible for ensuring data preservation and reuse ?**

The PI, Lutgarde Arckens.

**Who bears the end responsibility for updating & implementing this DMP?**

The PI bears the end responsibility of updating & implementing this DMP.